MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Morphosys Ag (OP:MPSYF)

73.27 UNCHANGED
Last Price Updated: 3:33 PM EDT, Jul 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 73.27
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 73.27
Today's Range 73.27 - 73.27
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
Via ACCESSWIRE
News headline image
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
Via ACCESSWIRE

Performance

More News

Read More
News headline image
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Via ACCESSWIRE
News headline image
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
Via ACCESSWIRE
News headline image
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
Via ACCESSWIRE
News headline image
Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
Via ACCESSWIRE
News headline image
Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023
Via ACCESSWIRE
News headline image
MorphoSys AG: Financial Calendar 2023
Via ACCESSWIRE
News headline image
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
Via ACCESSWIRE
News headline image
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
News headline image
Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Via ACCESSWIRE
News headline image
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
Via ACCESSWIRE
News headline image
MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
Via ACCESSWIRE
News headline image
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
Via ACCESSWIRE
News headline image
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
Via ACCESSWIRE
News headline image
Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
Via ACCESSWIRE
News headline image
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Via ACCESSWIRE
News headline image
Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
Via ACCESSWIRE
News headline image
MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
Via ACCESSWIRE
News headline image
MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
Via ACCESSWIRE
News headline image
MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
Via ACCESSWIRE
News headline image
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
Via ACCESSWIRE
News headline image
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
Via ACCESSWIRE
News headline image
GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
Via ACCESSWIRE
News headline image
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
From MorphoSys AG
Via AccessWire

Frequently Asked Questions

Is Morphosys Ag publicly traded?
Yes, Morphosys Ag is publicly traded.
What exchange does Morphosys Ag trade on?
Morphosys Ag trades on the OTC Traded
What is the ticker symbol for Morphosys Ag?
The ticker symbol for Morphosys Ag is MPSYF on the OTC Traded
What is the current price of Morphosys Ag?
The current price of Morphosys Ag is 73.27
When was Morphosys Ag last traded?
The last trade of Morphosys Ag was at 07/09/24 03:33 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story